CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy
NCT02537977
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Leukemia
Lymphoma
Interventions
BIOLOGICAL:
CD19-directed CAR-T cells
Sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine